Cuellar D C, Kyprianou N
Department of Surgery, Division of Urology, The University of Maryland Medical System, Baltimore 21201, USA.
Curr Opin Urol. 2001 Jan;11(1):27-33. doi: 10.1097/00042307-200101000-00004.
The standard medical therapy for symptomatic benign prostatic hyperplasia is still alpha-blockers and 5alpha-reductase inhibitors. Ongoing studies demonstrate the long-term safety and efficacy of these two classes of therapeutic approaches. Although there have been no new Food and Drug Administration approved medical therapies for the treatment of benign prostatic hyperplasia over the past year, interest in and the use of phytotherapeutic agents continues to increase. In this review, we will discuss the developments that have occurred over the past year in the medical management of benign prostatic hyperplasia. In addition, we present ongoing efforts at our center to obtain a better understanding of and manipulate the apoptotic pathway as it pertains to the pathophysiology of benign prostatic hyperplasia.
症状性良性前列腺增生的标准药物治疗仍然是α受体阻滞剂和5α还原酶抑制剂。正在进行的研究证明了这两类治疗方法的长期安全性和有效性。尽管在过去一年中美国食品药品监督管理局没有批准用于治疗良性前列腺增生的新药物疗法，但植物治疗剂的关注度和使用量仍在不断增加。在这篇综述中，我们将讨论过去一年中良性前列腺增生药物治疗方面的进展。此外，我们还介绍了我们中心正在进行的努力，以更好地理解和调控与良性前列腺增生病理生理学相关的细胞凋亡途径。
